Multidisciplinary Approaches for Transthyretin Amyloidosis

Haruki Koike, Takahiro Okumura, Toyoaki Murohara, Masahisa Katsuno, Haruki Koike, Takahiro Okumura, Toyoaki Murohara, Masahisa Katsuno

Abstract

Amyloidosis caused by systemic deposition of transthyretin (TTR) is called ATTR amyloidosis and mainly includes hereditary ATTR (ATTRv) amyloidosis and wild-type ATTR (ATTRwt) amyloidosis. Until recently, ATTRv amyloidosis had been considered a disease in the field of neurology because neuropathic symptoms predominated in patients described in early reports, whereas advances in diagnostic techniques and increased recognition of this disease revealed the presence of patients with cardiomyopathy as a predominant feature. In contrast, ATTRwt amyloidosis has been considered a disease in the field of cardiology. However, recent studies have suggested that some of the patients with ATTRwt amyloidosis present tenosynovial tissue complications, particularly carpal tunnel syndrome, as an initial manifestation of amyloidosis, necessitating an awareness of this disease among neurologists and orthopedists. Although histopathological confirmation of amyloid deposits has traditionally been considered mandatory for the diagnosis of ATTR amyloidosis, the development of noninvasive imaging techniques in the field of cardiology, such as echocardiography, magnetic resonance imaging, and nuclear imaging, enabled nonbiopsy diagnosis of this disease. The mechanisms underlying characteristic cardiac imaging findings have been deciphered by histopathological studies. Novel disease-modifying therapies for ATTR amyloidosis, such as TTR stabilizers, short interfering RNA, and antisense oligonucleotides, were initially approved for ATTRv amyloidosis patients with polyneuropathy. However, the indications for the use of these disease-modifying therapies gradually widened to include ATTRv and ATTRwt amyloidosis patients with cardiomyopathy. Since the coronavirus disease 2019 (COVID-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, occurred, the minimization of hospital visits and telemedicine have become increasingly important. As older age and cardiovascular disease are major factors associated with increased disease severity and mortality of COVID-19, many ATTR amyloidosis patients are at increased risk of disease aggravation when they are infected with SARS-CoV-2. From this viewpoint, close interspecialty communication to determine the optimal interval of evaluation is needed for the management of patients with ATTR amyloidosis.

Keywords: Amyloid angiopathy; Cardiac amyloidosis; Inotersen; Patisiran; Positron emission tomography; Protein misfolding disease; Red flag; Scintigraphy; Tafamidis; Treatment.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Representative B-mode echocardiography findings of ATTR amyloidosis. a A thickened interventricular septum with hyperrefractile myocardial echoes (i.e., a granular sparkling appearance) is observed in the long-axis view (arrows). b Concentric hypertrophy of the ventricular wall is demonstrated in the short-axis view
Fig. 2
Fig. 2
Two-dimensional speckle-tracking strain imaging of echocardiography in a late-onset ATTRVal30Met amyloidosis patient from a nonendemic area of Japan. Reduced left ventricular longitudinal strain in the middle and basal segments with relatively preserved strain in the apex (i.e., apical sparing) is observed. A bull’s eye plot is shown in the lower right panel
Fig. 3
Fig. 3
Gadolinium-enhanced cardiac magnetic resonance imaging in a patient with ATTRwt amyloidosis. a Late gadolinium enhancement is observed along with the myocardial walls in an axial section. b The left ventricular wall shows diffuse subendocardial or transmural late gadolinium enhancement without a coronary distribution pattern
Fig. 4
Fig. 4
Microangiopathy in a late-onset ATTRVal30Met amyloidosis patient from a nonendemic area of Japan. A cross section of a sural nerve biopsy specimen. Uranyl acetate and lead citrate-stained specimens. The continuity of the endothelial cells of an endoneurial microvessel is lost (arrows), indicating the disruption of the blood–nerve barrier at this site. Scale bar 2 μm
Fig. 5
Fig. 5
Myocardial T1 mapping of magnetic resonance imaging in a late-onset ATTRVal30Met amyloidosis patient from a nonendemic area of Japan. Native myocardial T1 mapping indicates abnormally increased T1 relaxation time
Fig. 6.
Fig. 6.
99mTc-Pyrophosphate cardiac scintigraphy images in a late-onset ATTRVal30Met amyloidosis patient from a nonendemic area of Japan. a Myocardial uptake of the 99mTc-pyrophosphate tracer is observed on axial planes of single-photon emission computed tomography (SPECT). b Plain computed tomography (CT) images that correspond to a. c Reconstruction of SPECT images linked to plain CT images
Fig. 7
Fig. 7
Differential characteristics of amyloid deposits between early onset ATTRVal30Met amyloidosis patients from conventional endemic foci (a–c) and late-onset ATTRVal30Met amyloidosis patients from nonendemic areas (d–f). Biopsy specimens of the sural nerve (a, d) and autopsy specimens of the heart (b, c, e, f). Uranyl acetate and lead citrate-stained specimens (a, d). Alkaline Congo red-stained specimens (b, c, e, f). On electron microscopy, amyloid fibrils tend to be long and thick in early onset patients from endemic foci (a). On light microscopy, amyloid deposits tend to be highly congophilic (b) and exhibit a strong apple-green birefringence under polarized light (c) in early onset patients from endemic foci. The atrophy and degeneration of myocardial cells result in the formation of amyloid rings (arrowhead). In late-onset patients from nonendemic areas, amyloid fibrils are generally short and thin on electron microscopy (d). On light microscopy, amyloid deposits are generally weakly congophilic (e) and exhibit a faint apple-green birefringence (f) in late-onset patients from nonendemic areas. Compared with (b), the atrophy of myocardial cells is not conspicuous despite massive amyloid deposition in (e). Scale bars 0.2 μm (a and d) and 20 μm (b, C, e, and f)

References

    1. Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387–404. doi: 10.1038/s41582-019-0210-4.
    1. Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva MJM, Sekijima Y, Sipe JD, Westermark P. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid. 2020;27(4):217–222. doi: 10.1080/13506129.2020.1835263.
    1. Koike H, Katsuno M. Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies. Neurol Ther. 2020;9(2):317–333. doi: 10.1007/s40120-020-00210-7.
    1. Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952;75(3):408–427. doi: 10.1093/brain/75.3.408.
    1. Araki S, Mawatari S, Ohta M, Nakajima A, Kuroiwa Y. Polyneuritic amyloidosis in a Japanese family. Arch Neurol. 1968;18(6):593–602. doi: 10.1001/archneur.1968.00470360015001.
    1. Andersson R. Familial amyloidosis with polyneuropathy. A clinical study based on patients living in Northern Sweden. Acta Med Scand Suppl. 1976;590:1–64.
    1. Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, Biagini E, Salvi F, Branzi A. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7(7):398–408. doi: 10.1038/nrcardio.2010.67.
    1. Koike H, Tanaka F, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Fujitake J, Kawanami T, Kato T, Yamamoto M, Sobue G. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry. 2012;83(2):152–158. doi: 10.1136/jnnp-2011-301299.
    1. Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, Ando Y. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis. 2018;13(1):6. doi: 10.1186/s13023-017-0726-x.
    1. Cornwell GG, III, Murdoch WL, Kyle RA, Westermark P, Pitkänen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med. 1983;75(4):618–623. doi: 10.1016/0002-9343(83)90443-6.
    1. Martinez-Naharro A, Baksi AJ, Hawkins PN, Fontana M. Diagnostic imaging of cardiac amyloidosis. Nat Rev Cardiol. 2020;17(7):413–426. doi: 10.1038/s41569-020-0334-7.
    1. Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, Nair AP, Nativi-Nicolau J, Ruberg FL, American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142(1):e7–e22. doi: 10.1161/CIR.0000000000000792.
    1. Sekijima Y, Yazaki M, Ueda M, Koike H, Yamada M, Ando Y. First nationwide survey on systemic wild-type ATTR amyloidosis in Japan. Amyloid. 2018;25(1):8–10. doi: 10.1080/13506129.2017.1409706.
    1. Cappelli F, Zampieri M, Fumagalli C, Nardi G, Del Monaco G, Matucci Cerinic M, Allinovi M, Taborchi G, Martone R, Gabriele M, Ungar A, Moggi Pignone A, Marchionni N, Di Mario C, Olivotto I, Perfetto F. Tenosynovial complications identify TTR cardiac amyloidosis among patients with hypertrophic cardiomyopathy phenotype. J Intern Med. 2021;289(6):831–9.
    1. Vianello PF, La Malfa G, Tini G, Mazzola V, Miceli A, Santolini E, Briano S, Porto I, Canepa M. Prevalence of transthyretin amyloid cardiomyopathy in male patients who underwent bilateral carpal tunnel surgery: the ACTUAL study. Int J Cardiol. 2021;15(329):144–147. doi: 10.1016/j.ijcard.2020.12.044.
    1. Westermark P, Westermark GT, Suhr OB, Berg S. Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis. Ups J Med Sci. 2014;119(3):223–228. doi: 10.3109/03009734.2014.895786.
    1. Yanagisawa A, Ueda M, Sueyoshi T, Okada T, Fujimoto T, Ogi Y, Kitagawa K, Tasaki M, Misumi Y, Oshima T, Jono H, Obayashi K, Hirakawa K, Uchida H, Westermark P, Ando Y, Mizuta H. Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis. Mod Pathol. 2015;28(2):201–207. doi: 10.1038/modpathol.2014.102.
    1. Okumura T, Murohara T. Advantages and emerging problems of novel treatments for transthyretin cardiac amyloidosis. Circ J. 2019;84(1):9–10. doi: 10.1253/circj.CJ-19-1044.
    1. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554–1568. doi: 10.1093/eurheartj/ehab072.
    1. Kelly JW. Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases. Structure. 1997;5(5):595–600. doi: 10.1016/S0969-2126(97)00215-3.
    1. Koike H, Katsuno M. Ultrastructure in transthyretin amyloidosis: from pathophysiology to therapeutic insights. Biomedicines. 2019;7(1):11. doi: 10.3390/biomedicines7010011.
    1. Sekijima Y, Wiseman RL, Matteson J, Hammarström P, Miller SR, Sawkar AR, Balch WE, Kelly JW. The biological and chemical basis for tissue-selective amyloid disease. Cell. 2005;121(1):73–85. doi: 10.1016/j.cell.2005.01.018.
    1. Koike H, Misu K, Ikeda S, Ando Y, Nakazato M, Ando E, Yamamoto M, Hattori N, Sobue G, Study Group for Hereditary Neuropathy in Japan Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol. 2002;59(11):1771–1776. doi: 10.1001/archneur.59.11.1771.
    1. Koike H, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Tanaka F, Sobue G. Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid. 2011;18(2):53–62. doi: 10.3109/13506129.2011.565524.
    1. Koike H, Nakamura T, Nishi R, Ikeda S, Kawagashira Y, Iijima M, Katsuno M, Sobue G. Widespread cardiac and vasomotor autonomic dysfunction in non-Val30Met hereditary transthyretin amyloidosis. Intern Med. 2018;57(23):3365–3370. doi: 10.2169/internalmedicine.1113-18.
    1. Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet Med. 2017;19(7):733–742. doi: 10.1038/gim.2016.200.
    1. Damrauer SM, Chaudhary K, Cho JH, Liang LW, Argulian E, Chan L, Dobbyn A, Guerraty MA, Judy R, Kay J, Kember RL, Levin MG, Saha A, Van Vleck T, Verma SS, Weaver J, Abul-Husn NS, Baras A, Chirinos JA, Drachman B, Kenny EE, Loos RJF, Narula J, Overton J, Reid J, Ritchie M, Sirugo G, Nadkarni G, Rader DJ, Do R. Association of the V122I hereditary transthyretin amyloidosis genetic variant with heart failure among individuals of African or Hispanic/Latino ancestry. JAMA. 2019;322(22):2191–2202. doi: 10.1001/jama.2019.17935.
    1. Gentile L, Di Bella G, Minutoli F, Cucinotta F, Obici L, Mussinelli R, Arimatea I, Russo M, Toscano A, Vita G, Mazzeo A. Description of a large cohort of Caucasian patients with V122I ATTRv amyloidosis: Neurological and cardiological features. J Peripher Nerv Syst. 2020;25(3):273–278. doi: 10.1111/jns.12385.
    1. Schneider F, Hammarström P, Kelly JW. Transthyretin slowly exchanges subunits under physiological conditions: a convenient chromatographic method to study subunit exchange in oligomeric proteins. Protein Sci. 2001;10(8):1606–1613. doi: 10.1110/ps.8901.
    1. Suhr OB, Lundgren E, Westermark P. One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition. J Intern Med. 2017;281(4):337–347. doi: 10.1111/joim.12585.
    1. Pras M, Franklin EC, Prelli F, Frangione B. A variant of prealbumin from amyloid fibrils in familial polyneuropathy of Jewish origin. J Exp Med. 1981;154(3):989–993. doi: 10.1084/jem.154.3.989.
    1. Bergström J, Gustavsson A, Hellman U, Sletten K, Murphy CL, Weiss DT, Solomon A, Olofsson BO, Westermark P. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol. 2005;206(2):224–232. doi: 10.1002/path.1759.
    1. Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997;336(7):466–473. doi: 10.1056/NEJM199702133360703.
    1. Ueda M, Horibata Y, Shono M, Misumi Y, Oshima T, Su Y, Tasaki M, Shinriki S, Kawahara S, Jono H, Obayashi K, Ogawa H, Ando Y. Clinicopathological features of senile systemic amyloidosis: an ante- and post-mortem study. Mod Pathol. 2011;24(12):1533–1544. doi: 10.1038/modpathol.2011.117.
    1. González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–2594. doi: 10.1093/eurheartj/ehv338.
    1. Griffin JM, Maurer MS. Transthyretin cardiac amyloidosis: a treatable form of heart failure with a preserved ejection fraction. Trends Cardiovasc Med. 2021;31(1):59–66. doi: 10.1016/j.tcm.2019.12.003.
    1. Stein K, Störkel S, Linke RP, Goebel HH. Chemical heterogeneity of amyloid in the carpal tunnel syndrome. Virchows Arch A Pathol Anat Histopathol. 1987;412(1):37–45. doi: 10.1007/BF00750729.
    1. Kyle RA, Gertz MA, Linke RP. Amyloid localized to tenosynovium at carpal tunnel release. Immunohistochemical identification of amyloid type. Am J Clin Pathol. 1992;97(2):250–253. doi: 10.1093/ajcp/97.2.250.
    1. Sekijima Y, Uchiyama S, Tojo K, Sano K, Shimizu Y, Imaeda T, Hoshii Y, Kato H, Ikeda S. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol. 2011;42(11):1785–1791. doi: 10.1016/j.humpath.2011.03.004.
    1. Sueyoshi T, Ueda M, Jono H, Irie H, Sei A, Ide J, Ando Y, Mizuta H. Wild-type transthyretin-derived amyloidosis in various ligaments and tendons. Hum Pathol. 2011;42(9):1259–1264. doi: 10.1016/j.humpath.2010.11.017.
    1. Eldhagen P, Berg S, Lund LH, Sörensson P, Suhr OB, Westermark P. Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis. J Intern Med. 2021;289(6):895–905. doi: 10.1111/joim.13222.
    1. Koike H, Misu K, Sugiura M, Iijima M, Mori K, Yamamoto M, Hattori N, Mukai E, Ando Y, Ikeda S, Sobue G. Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology. 2004;63(1):129–138. doi: 10.1212/01.WNL.0000132966.36437.12.
    1. Koike H, Kawagashira Y, Iijima M, Yamamoto M, Hattori N, Tanaka F, Hirayama M, Ando Y, Ikeda S, Sobue G. Electrophysiological features of late-onset transthyretin Met30 familial amyloid polyneuropathy unrelated to endemic foci. J Neurol. 2008;255(10):1526–1533. doi: 10.1007/s00415-008-0962-z.
    1. Koike H, Morozumi S, Kawagashira Y, Iijima M, Yamamoto M, Hattori N, Tanaka F, Nakamura T, Hirayama M, Ando Y, Ikeda S, Sobue G. The significance of carpal tunnel syndrome in transthyretin Val30Met familial amyloid polyneuropathy. Amyloid. 2009;16(3):142–148. doi: 10.1080/13506120903094074.
    1. Ebenezer GJ, Liu Y, Judge DP, Cunningham K, Truelove S, Carter ND, Sebastian B, Byrnes K, Polydefkis M. Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy. Ann Neurol. 2017;82(1):44–56. doi: 10.1002/ana.24972.
    1. Chao CC, Hsueh HW, Kan HW, Liao CH, Jiang HH, Chiang H, Lin WM, Yeh TY, Lin YH, Cheng YY, Hsieh ST. Skin nerve pathology: biomarkers of premanifest and manifest amyloid neuropathy. Ann Neurol. 2019;85(4):560–573. doi: 10.1002/ana.25433.
    1. Chiang MC, Yeh TY, Sung JY, Hsueh HW, Kao YH, Hsueh SJ, Chang KC, Feng FP, Lin YH, Chao CC, Hsieh ST. Early changes of nerve integrity in preclinical carriers of hereditary transthyretin Ala117Ser amyloidosis with polyneuropathy. Eur J Neurol. 2021;28(3):982–991. doi: 10.1111/ene.14698.
    1. Marume K, Takashio S, Nishi M, Hirakawa K, Yamamoto M, Hanatani S, Oda S, Utsunomiya D, Shiraishi S, Ueda M, Yamashita T, Sakamoto K, Yamamoto E, Kaikita K, Izumiya Y, Yamashita Y, Ando Y, Tsujita K. Combination of commonly examined parameters is a useful predictor of positive 99mTc-labeled pyrophosphate scintigraphy findings in elderly patients with suspected transthyretin cardiac amyloidosis. Circ J. 2019;83(8):1698–1708. doi: 10.1253/circj.CJ-19-0255.
    1. Ikeda S. Cardiac amyloidosis: heterogenous pathogenic backgrounds. Intern Med. 2004;43(12):1107–1114. doi: 10.2169/internalmedicine.43.1107.
    1. Koike H, Nakamura T, Hashizume A, Nishi R, Ikeda S, Kawagashira Y, Iijima M, Katsuno M, Sobue G. Cardiac and peripheral vasomotor autonomic functions in late-onset transthyretin Val30Met familial amyloid polyneuropathy. J Neurol. 2017;264(11):2293–2302. doi: 10.1007/s00415-017-8629-2.
    1. Koike H, Ando Y, Ueda M, Kawagashira Y, Iijima M, Fujitake J, Hayashi M, Yamamoto M, Mukai E, Nakamura T, Katsuno M, Hattori N, Sobue G. Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy. J Neurol Sci. 2009;287(1–2):178–184. doi: 10.1016/j.jns.2009.07.028.
    1. Koike H, Nishi R, Ikeda S, Kawagashira Y, Iijima M, Sakurai T, Shimohata T, Katsuno M, Sobue G. The morphology of amyloid fibrils and their impact on tissue damage in hereditary transthyretin amyloidosis: an ultrastructural study. J Neurol Sci. 2018;15(394):99–106. doi: 10.1016/j.jns.2018.09.011.
    1. Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN. Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA. 2004;101(9):2817–2822. doi: 10.1073/pnas.0400062101.
    1. Ueda M, Sekijima Y, Koike H, Yamashita T, Yoshinaga T, Ishii T, Ando Y. Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies. J Neurol Sci. 2020;15(414):116813. doi: 10.1016/j.jns.2020.116813.
    1. Koike H, Mouri N, Fukami Y, Iijima M, Matsuo K, Yagi N, Saito A, Nakamura H, Takahashi K, Nakae Y, Okada Y, Tanaka F, Sobue G, Katsuno M. Two distinct mechanisms of neuropathy in immunoglobulin light chain (AL) amyloidosis. J Neurol Sci. 2021;2(421):117305. doi: 10.1016/j.jns.2020.117305.
    1. Ueda M, Misumi Y, Mizuguchi M, Nakamura M, Yamashita T, Sekijima Y, Ota K, Shinriki S, Jono H, Ikeda S, Suhr OB, Ando Y. SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy. Clin Chem. 2009;55(6):1223–1227. doi: 10.1373/clinchem.2008.118505.
    1. Klein CJ, Vrana JA, Theis JD, Dyck PJ, Dyck PJ, Spinner RJ, Mauermann ML, Bergen HR, III, Zeldenrust SR, Dogan A. Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue. Arch Neurol. 2011;68(2):195–199. doi: 10.1001/archneurol.2010.261.
    1. Benson MD, Dasgupta NR, Rao R. Diagnosis and screening of patients with hereditary transthyretin amyloidosis (hATTR): current strategies and guidelines. Ther Clin Risk Manag. 2020;14(16):749–758. doi: 10.2147/TCRM.S185677.
    1. Granstam SO, Rosengren S, Vedin O, Kero T, Sörensen J, Carlson K, Flachskampf FA, Wikström G. Evaluation of patients with cardiac amyloidosis using echocardiography, ECG and right heart catheterization. Amyloid. 2013;20(1):27–33. doi: 10.3109/13506129.2012.761967.
    1. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation. 2003;107(19):2446–2452. doi: 10.1161/01.CIR.0000068313.67758.4F.
    1. Bellavia D, Abraham TP, Pellikka PA, Al-Zahrani GB, Dispenzieri A, Oh JK, Bailey KR, Wood CM, Novo S, Miyazaki C, Miller FA., Jr Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. J Am Soc Echocardiogr. 2007;20(10):1194–1202. doi: 10.1016/j.echo.2007.02.025.
    1. Ogiwara F, Koyama J, Ikeda S, Kinoshita O, Falk RH. Comparison of the strain Doppler echocardiographic features of familial amyloid polyneuropathy (FAP) and light-chain amyloidosis. Am J Cardiol. 2005;95(4):538–540. doi: 10.1016/j.amjcard.2004.10.029.
    1. Phelan D, Thavendiranathan P, Popovic Z, Collier P, Griffin B, Thomas JD, Marwick TH. Application of a parametric display of two-dimensional speckle-tracking longitudinal strain to improve the etiologic diagnosis of mild to moderate left ventricular hypertrophy. J Am Soc Echocardiogr. 2014;27(8):888–895. doi: 10.1016/j.echo.2014.04.015.
    1. Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, Gagliardi C, Milandri A, Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, Biagini E, Salvi F, Branzi A. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7(7):398–408. doi: 10.1038/nrcardio.2010.67.
    1. Podnar S, Sarafov S, Tournev I, Omejec G, Zidar J. Peripheral nerve ultrasonography in patients with transthyretin amyloidosis. Clin Neurophysiol. 2017;128(4):505–511. doi: 10.1016/j.clinph.2017.01.013.
    1. Salvalaggio A, Coraci D, Cacciavillani M, Padua L, Briani C. Nerve ultrasonography features in hereditary transthyretin amyloidosis with V30M mutation and polyneuropathy. Neurol Sci. (In press).
    1. Misumi Y, Ueda M, Yamashita T, Masuda T, Kinoshita Y, Tasaki M, Nagase T, Ando Y. Novel screening for transthyretin amyloidosis by using fat ultrasonography. Ann Neurol. 2017;81(4):604–608. doi: 10.1002/ana.24914.
    1. Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson. 2008;10(1):54. doi: 10.1186/1532-429X-10-54.
    1. Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, Kotecha T, Francis R, Hutt DF, Rezk T, Rosmini S, Quarta CC, Whelan CJ, Kellman P, Gillmore JD, Moon JC, Hawkins PN, Fontana M. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2017;70(4):466–477. doi: 10.1016/j.jacc.2017.05.053.
    1. Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, Maestrini V, Barcella W, Rosmini S, Bulluck H, Sayed RH, Patel K, Mamhood S, Bucciarelli-Ducci C, Whelan CJ, Herrey AS, Lachmann HJ, Wechalekar AD, Manisty CH, Schelbert EB, Kellman P, Gillmore JD, Hawkins PN, Moon JC. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132(16):1570–1579. doi: 10.1161/CIRCULATIONAHA.115.016567.
    1. Dungu JN, Valencia O, Pinney JH, Gibbs SD, Rowczenio D, Gilbertson JA, Lachmann HJ, Wechalekar A, Gillmore JD, Whelan CJ, Hawkins PN, Anderson LJ. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):133–142. doi: 10.1016/j.jcmg.2013.08.015.
    1. Koike H, Ikeda S, Takahashi M, Kawagashira Y, Iijima M, Misumi Y, Ando Y, Ikeda SI, Katsuno M, Sobue G. Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy. Neurology. 2016;87(21):2220–2229. doi: 10.1212/WNL.0000000000003362.
    1. Kotecha T, Martinez-Naharro A, Treibel TA, Francis R, Nordin S, Abdel-Gadir A, Knight DS, Zumbo G, Rosmini S, Maestrini V, Bulluck H, Rakhit RD, Wechalekar AD, Gilbertson J, Sheppard MN, Kellman P, Gillmore JD, Moon JC, Hawkins PN, Fontana M. Myocardial edema and prognosis in amyloidosis. J Am Coll Cardiol. 2018;71(25):2919–2931. doi: 10.1016/j.jacc.2018.03.536.
    1. Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, Pica S, Castelletti S, Piechnik SK, Robson MD, Gilbertson JA, Rowczenio D, Hutt DF, Lachmann HJ, Wechalekar AD, Whelan CJ, Gillmore JD, Hawkins PN, Moon JC. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7(2):157–165. doi: 10.1016/j.jcmg.2013.10.008.
    1. Fontana M, Banypersad SM, Treibel TA, Abdel-Gadir A, Maestrini V, Lane T, Gilbertson JA, Hutt DF, Lachmann HJ, Whelan CJ, Wechalekar AD, Herrey AS, Gillmore JD, Hawkins PN, Moon JC. Differential myocyte responses in patients with cardiac transthyretin amyloidosis and light-chain amyloidosis: a cardiac MR imaging study. Radiology. 2015;277(2):388–397. doi: 10.1148/radiol.2015141744.
    1. Oda S, Utsunomiya D, Nakaura T, Yuki H, Kidoh M, Morita K, Takashio S, Yamamuro M, Izumiya Y, Hirakawa K, Ishida T, Tsujita K, Ueda M, Yamashita T, Ando Y, Hata H, Yamashita Y. Identification and assessment of cardiac amyloidosis by myocardial strain analysis of cardiac magnetic resonance imaging. Circ J. 2017;81(7):1014–1021. doi: 10.1253/circj.CJ-16-1259.
    1. Treibel TA, Bandula S, Fontana M, White SK, Gilbertson JA, Herrey AS, Gillmore JD, Punwani S, Hawkins PN, Taylor SA, Moon JC. Extracellular volume quantification by dynamic equilibrium cardiac computed tomography in cardiac amyloidosis. J Cardiovasc Comput Tomogr. 2015;9(6):585–592. doi: 10.1016/j.jcct.2015.07.001.
    1. Chevance V, Damy T, Tacher V, Legou F, Ridouani F, Luciani A, Kobeiter H, Rahmouni A, Deux JF. Myocardial iodine concentration measurement using dual-energy computed tomography for the diagnosis of cardiac amyloidosis: a pilot study. Eur Radiol. 2018;28(2):816–823. doi: 10.1007/s00330-017-4984-8.
    1. Khalique Z, Ferreira PF, Scott AD, Nielles-Vallespin S, Martinez-Naharro A, Fontana M, Hawkins P, Firmin DN, Pennell DJ. Diffusion tensor cardiovascular magnetic resonance in cardiac amyloidosis. Circ Cardiovasc Imaging. 2020;13(5):e009901. doi: 10.1161/CIRCIMAGING.119.009901.
    1. Kollmer J, Hund E, Hornung B, Hegenbart U, Schönland SO, Kimmich C, Kristen AV, Purrucker J, Röcken C, Heiland S, Bendszus M, Pham M. In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography. Brain. 2015;138(Pt 3):549–562. doi: 10.1093/brain/awu344.
    1. Kollmer J, Sahm F, Hegenbart U, Purrucker JC, Kimmich C, Schönland SO, Hund E, Heiland S, Hayes JM, Kristen AV, Röcken C, Pham M, Bendszus M, Weiler M. Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools. Neurology. 2017;89(5):475–484. doi: 10.1212/WNL.0000000000004178.
    1. Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, Pozniakoff T, Ruberg FL, Miller EJ, Berk JL, Dispenzieri A, Grogan M, Johnson G, Bokhari S, Maurer MS. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016;1(8):880–889. doi: 10.1001/jamacardio.2016.2839.
    1. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–2412. doi: 10.1161/CIRCULATIONAHA.116.021612.
    1. Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, Otto CA, Swanson DP, Beierwaltes WH. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med. 1981;22(1):22–31.
    1. Schofer J, Spielmann R, Schuchert A, Weber K, Schlüter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1988;12(5):1252–1258. doi: 10.1016/0735-1097(88)92608-3.
    1. Ando Y, Obayashi K, Tanaka Y, Tsuji T, Uchino M, Takahashi M, Ando M. Radiolabelled meta-iodobenzylguanidine in assessment of autonomic dysfunction. Lancet. 1994;343(8903):984–985. doi: 10.1016/S0140-6736(94)90113-9.
    1. Rosengren S, Skibsted Clemmensen T, Tolbod L, Granstam SO, Eiskjær H, Wikström G, Vedin O, Kero T, Lubberink M, Harms HJ, Flachskampf FA, Baron T, Carlson K, Mikkelsen F, Antoni G, Frost Andersen N, Hvitfeldt Poulsen S, Sörensen J. Diagnostic accuracy of [11C]PIB positron emission tomography for detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2020;13(6):1337–1347. doi: 10.1016/j.jcmg.2020.02.023.
    1. Law WP, Wang WY, Moore PT, Mollee PN, Ng AC. Cardiac amyloid imaging with 18F-Florbetaben PET: a pilot study. J Nucl Med. 2016;57(11):1733–1739. doi: 10.2967/jnumed.115.169870.
    1. Park MA, Padera RF, Belanger A, Dubey S, Hwang DH, Veeranna V, Falk RH, Di Carli MF, Dorbala S. 18F-florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: autoradiography study. Circ Cardiovasc Imaging. 2015;8(8):e002954. doi: 10.1161/CIRCIMAGING.114.002954.
    1. Sekijima Y, Yazaki M, Oguchi K, Ezawa N, Yoshinaga T, Yamada M, Yahikozawa H, Watanabe M, Kametani F, Ikeda S. Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis. Neurology. 2016;87(8):773–781. doi: 10.1212/WNL.0000000000003001.
    1. Ezawa N, Katoh N, Oguchi K, Yoshinaga T, Yazaki M, Sekijima Y. Visualization of multiple organ amyloid involvement in systemic amyloidosis using 11C-PiB PET imaging. Eur J Nucl Med Mol Imaging. 2018;45(3):452–461. doi: 10.1007/s00259-017-3814-1.
    1. Takasone K, Katoh N, Takahashi Y, Abe R, Ezawa N, Yoshinaga T, Yanagisawa S, Yazaki M, Oguchi K, Koyama J, Sekijima Y. Non-invasive detection and differentiation of cardiac amyloidosis using 99mTc-pyrophosphate scintigraphy and 11C-Pittsburgh compound B PET imaging. Amyloid. 2020;27(4):266–274. doi: 10.1080/13506129.2020.1798223.
    1. Miyazaki Y, Koike H, Akane A, Shibata Y, Nishiwaki K, Sobue G. Spinal cord stimulation markedly ameliorated refractory neuropathic pain in transthyretin Val30Met familial amyloid polyneuropathy. Amyloid. 2011;18(2):87–90. doi: 10.3109/13506129.2011.569782.
    1. Ando E, Ando Y, Okamura R, Uchino M, Ando M, Negi A. Ocular manifestations of familial amyloidotic polyneuropathy type I: long-term follow up. Br J Ophthalmol. 1997;81(4):295–298. doi: 10.1136/bjo.81.4.295.
    1. Ando Y, Ohlsson PI, Suhr O, Nyhlin N, Yamashita T, Holmgren G, Danielsson A, Sandgren O, Uchino M, Ando M. A new simple and rapid screening method for variant transthyretin-related amyloidosis. Biochem Biophys Res Commun. 1996;228(2):480–483. doi: 10.1006/bbrc.1996.1685.
    1. Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S, Andersen O, Karlberg I, Nordén G, Nakazato M, Hawkins P, Richardson S, Pepys M. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30) Clin Genet. 1991;40(3):242–246. doi: 10.1111/j.1399-0004.1991.tb03085.x.
    1. Yamashita T, Ando Y, Okamoto S, Misumi Y, Hirahara T, Ueda M, Obayashi K, Nakamura M, Jono H, Shono M, Asonuma K, Inomata Y, Uchino M. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology. 2012;78(9):637–643. doi: 10.1212/WNL.0b013e318248df18.
    1. Yazaki M, Mitsuhashi S, Tokuda T, Kametani F, Takei YI, Koyama J, Kawamorita A, Kanno H, Ikeda SI. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant. 2007;7(1):235–242. doi: 10.1111/j.1600-6143.2006.01585.x.
    1. Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology. 2010;75(4):324–327. doi: 10.1212/WNL.0b013e3181ea15d4.
    1. Koike H, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Nakamura T, Watanabe H, Kamei H, Kiuchi T, Sobue G. Impact of aging on the progression of neuropathy after liver transplantation in transthyretin Val30Met amyloidosis. Muscle Nerve. 2012;46(6):964–970. doi: 10.1002/mus.23480.
    1. Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, Furtado E, Barroso E, Daniel J, Samuel D, Adam R, Karam V, Poterucha J, Lewis D, Ferraz-Neto BH, Cruz MW, Munar-Ques M, Fabregat J, Ikeda S, Ando Y, Heaton N, Otto G, Suhr O. Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation. 2015;99(9):1847–1854. doi: 10.1097/TP.0000000000000574.
    1. Koike H, Fukami Y, Nishi R, Kawagashira Y, Iijima M, Sobue G, Katsuno M. Clinicopathological spectrum and recent advances in the treatment of hereditary transthyretin amyloidosis. Neurol Clin Neurosci. 2019;7:166–173. doi: 10.1111/ncn3.12306.
    1. Ando Y, Terazaki H, Nakamura M, Ando E, Haraoka K, Yamashita T, Ueda M, Okabe H, Sasaki Y, Tanihara H, Uchino M, Inomata Y. A different amyloid formation mechanism: de novo oculoleptomeningeal amyloid deposits after liver transplantation. Transplantation. 2004;77(3):345–349. doi: 10.1097/01.TP.0000111516.60013.E6.
    1. Peterson SA, Klabunde T, Lashuel HA, Purkey H, Sacchettini JC, Kelly JW. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc Natl Acad Sci USA. 1998;95(22):12956–12960. doi: 10.1073/pnas.95.22.12956.
    1. Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Investig. 2004;84(5):545–552. doi: 10.1038/labinvest.3700059.
    1. Obici L, Adams D. Acquired and inherited amyloidosis: knowledge driving patients' care. J Peripher Nerv Syst. 2020;25(2):85–101. doi: 10.1111/jns.12381.
    1. Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceição IM, Schmidt HH, Trigo P, Kelly JW, Labaudinière R, Chan J, Packman J, Wilson A, Grogan DR. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–792. doi: 10.1212/WNL.0b013e3182661eb1.
    1. Barroso FA, Judge DP, Ebede B, Li H, Stewart M, Amass L, Sultan MB. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017;24(3):194–204. doi: 10.1080/13506129.2017.1357545.
    1. Merlini G, Coelho T, Waddington Cruz M, Li H, Stewart M, Ebede B. Evaluation of mortality during long-term treatment with tafamidis for transthyretin amyloidosis with polyneuropathy: clinical trial results up to 8.5 years. Neurol Ther. 2020;9(1):105–115. doi: 10.1007/s40120-020-00180-w.
    1. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C, ATTR-ACT Study Investigators Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. doi: 10.1056/NEJMoa1805689.
    1. Hanna M, Damy T, Grogan M, Stewart M, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB, Maurer MS. Impact of tafamidis on health-related quality of life in patients with transthyretin amyloid cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial) Am J Cardiol. 2021;15(141):98–105. doi: 10.1016/j.amjcard.2020.10.066.
    1. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda S, Seldin DC, Merlini G, Skinner M, Kelly JW, Dyck PJ, Diflunisal Trial Consortium Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658–2667. doi: 10.1001/jama.2013.283815.
    1. Benson MD, Kluve-Beckerman B, Zeldenrust SR, Siesky AM, Bodenmiller DM, Showalter AD, Sloop KW. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve. 2006;33(5):609–618. doi: 10.1002/mus.20503.
    1. Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH, III, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21. doi: 10.1056/NEJMoa1716153.
    1. Minamisawa M, Claggett B, Adams D, Kristen AV, Merlini G, Slama MS, Dispenzieri A, Shah AM, Falk RH, Karsten V, Sweetser MT, Chen J, Riese R, Vest J, Solomon SD. Association of Patisiran, an RNA interference therapeutic, with regional left ventricular myocardial strain in hereditary transthyretin amyloidosis: the APOLLO study. JAMA Cardiol. 2019;4(5):466–472. doi: 10.1001/jamacardio.2019.0849.
    1. Solomon SD, Adams D, Kristen A, Grogan M, González-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH, III, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O. Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. 2019;139(4):431–443. doi: 10.1161/CIRCULATIONAHA.118.035831.
    1. Coelho T, Adams D, Conceição I, Waddington-Cruz M, Schmidt HH, Buades J, Campistol J, Berk JL, Polydefkis M, Wang JJ, Chen J, Sweetser MT, Gollob J, Suhr OB. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Orphanet J Rare Dis. 2020;15(1):179. doi: 10.1186/s13023-020-01399-4.
    1. Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH, III, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T, Patisiran Global OLE study group Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol. 2021;20(1):49–59. doi: 10.1016/S1474-4422(20)30368-9.
    1. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH, III, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22–31. doi: 10.1056/NEJMoa1716793.
    1. Brannagan TH, Wang AK, Coelho T, Waddington Cruz M, Polydefkis MJ, Dyck PJ, Plante-Bordeneuve V, Berk JL, Barroso F, Merlini G, Conceição I, Hughes SG, Kwoh J, Jung SW, Guthrie S, Pollock M, Benson MD, Gertz M, NEURO-TTR open-label extension investigators Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial. Eur J Neurol. 2020;27(8):1374–1381. doi: 10.1111/ene.14285.
    1. Dasgupta NR, Rissing SM, Smith J, Jung J, Benson MD. Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid. 2020;27(1):52–58. doi: 10.1080/13506129.2019.1685487.
    1. Viney NJ, Guo S, Tai LJ, Baker BF, Aghajan M, Jung SW, Yu RZ, Booten S, Murray H, Machemer T, Burel S, Murray S, Buchele G, Tsimikas S, Schneider E, Geary RS, Benson MD, Monia BP. Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Fail. 2021;8(1):652–661. doi: 10.1002/ehf2.13154.
    1. Coelho T, Ando Y, Benson MD, Berk JL, Waddington-Cruz M, Dyck PJ, Gillmore JD, Khella SL, Litchy WJ, Obici L, Monteiro C, Tai LJ, Viney NJ, Buchele G, Brambatti M, Jung SW, St L O'Dea L, Tsimikas S, Schneider E, Geary RS, Monia BP, Gertz M. Design and rationale of the global phase 3 NEURO-TTRansform study of antisense oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in hereditary transthyretin-mediated amyloid polyneuropathy. Neurol Ther. 2021;10(1):375–89.
    1. Buxbaum JN. Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials. Amyloid. 2019;26(2):55–65. doi: 10.1080/13506129.2019.1575201.
    1. Guidon AC, Amato AA. COVID-19 and neuromuscular disorders. Neurology. 2020;94(22):959–969. doi: 10.1212/WNL.0000000000009566.
    1. Sayer G, Horn EM, Farr MA, Axsom K, Kleet A, Gjerde C, Latif F, Sobol I, Kelley N, Lancet E, Halik C, Takeda K, Naka Y, Yuzefpolskaya M, Kumaraiah D, Colombo PC, Maurer MS, Uriel N. Transition of a large tertiary heart failure program in response to the COVID-19 pandemic: changes that will endure. Circ Heart Fail. 2020;13(9):e007516. doi: 10.1161/CIRCHEARTFAILURE.120.007516.
    1. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, Brown TS, Der Nigoghossian C, Zidar DA, Haythe J, Brodie D, Beckman JA, Kirtane AJ, Stone GW, Krumholz HM, Parikh SA. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75(18):2352–2371. doi: 10.1016/j.jacc.2020.03.031.
    1. Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, Salazar-Mather TP, Dumenco L, Savaria MC, Aung SN, Flanigan T, Michelow IC. Predictors of COVID-19 severity: a literature review. Rev Med Virol. 2021;31(1):1–10. doi: 10.1002/rmv.2146.
    1. Belli LS, Duvoux C, Karam V, Adam R, Cuervas-Mons V, Pasulo L, Loinaz C, Invernizzi F, Patrono D, Bhoori S, Ciccarelli O, Morelli MC, Castells L, Lopez-Lopez V, Conti S, Fondevila C, Polak W. COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry. Lancet Gastroenterol Hepatol. 2020;5(8):724–725. doi: 10.1016/S2468-1253(20)30183-7.
    1. Dumortier J, Duvoux C, Roux O, Altieri M, Barraud H, Besch C, Caillard S, Coilly A, Conti F, Dharancy S, Durand F, Francoz C, Garaix F, Houssel-Debry P, Kounis I, Lassailly G, Laverdure N, Leroy V, Mallet M, Mazzola A, Meunier L, Radenne S, Richardet JP, Vanlemmens C, Hazzan M, Saliba F, French Solid Organ Transplant COVID Registry; Groupe de Recherche Français en Greffe de Foie (GReF2) Covid-19 in liver transplant recipients: the French SOT COVID registry. Clin Res Hepatol Gastroenterol. 2021;45(4):101639. doi: 10.1016/j.clinre.2021.101639.
    1. Webb GJ, Moon AM, Barnes E, Barritt AS, Marjot T. Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients. J Hepatol. (In press).

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren